AstraZeneca plc (LON:AZN) Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN Phase III trial in resectable non-small cell lung cancer. Positive high-level results from a planned interim analysis..
AstraZeneca plc (LON:AZN) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable..
AstraZeneca plc (LON:AZN) Enhertu reduced the risk of disease progression or death by 50% vs. chemotherapy in patients with HER2-low metastatic breast cancer with HR-positive and HR-negative disease. AstraZeneca and Daiichi..
AstraZeneca plc (LON:AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally..
AstraZeneca PLC (LON:AZN) has announced its first quarter 2022 results. Revenue and EPS summary Q1 2022 % Change $m Actual CER1 – Product Sales ..
AstraZeneca plc (LON:AZN) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with unresectable or metastatic HER2-low..
AstraZeneca plc (LON:AZN) and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the..
Positive results from the PROpel Phase III trial showed AstraZeneca plc (LON:AZN) and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic..
AstraZeneca plc (LON:AZN) has completed the transfer of its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group (Covis..
AstraZeneca plc (LON:AZN) has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. The companies will jointly develop and commercialise eplontersen..
AstraZeneca plc (LON:AZN) and Amgen’s Tezspire (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with severe..
Stock in AstraZeneca EPIC code: LON:AZN has gained 1.6% or 141 points during the course of today’s session so far. Buyers seem confident during this period. The high for the..
Caledonia Mining Corporation plc (LON:CMCL) reported a record quarterly production this week of almost 19,000 ounces. Revenue in the Quarter was 32 per cent higher than in Q3 2020 due..
AstraZeneca PLC (LON:AZN) has announced its year to date and Q3 2021 results. – Total Revenue in the year to date, including Alexion from 21 July 2021, was $25,406m, representing..
Shares of Allergy Therapeutics with EPIC code: LON:AGY has risen 3.55% or 1.25 points during the course of today’s session so far. Investors have stayed positive while the stock has..
Shares of AstraZeneca EPIC code: LON:AZN has stepped up 1.48% or 133 points in today’s trading session so far. Traders have remained optimistic while the stock has been in play...
Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed AstraZeneca plc (LON:AZN) AZD7442, a long acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19..
Shares of Anglo American company symbol: LON:AAL has gained 2.29% or 57.5 points throughout the session so far. Buyers seem confident while the stock has been in play. The high..
The stock price for AstraZeneca with ticker code: LON:AZN has moved up 2.25% or 195 points during today’s session so far. Market buyers have remained optimistic throughout the session. The..
Positive high-level results from the PROpel Phase III trial showed AstraZeneca plc (LON:AZN) and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in..
